Search Results for: 134

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

March 11, 2024 08:00 ET ROCKVILLE, Md., March 11, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in one-on-one meetings at the BIO-Europe […]

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference Read More »

Theriva™ Biologics participará en la conferencia BIO-Europe Spring

March 11, 2024 08:00 ET ROCKVILLE, Maryland, March 11, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), empresa diversificada de fase clínica que investiga tratamientos antineoplásicos y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la dirección de la empresa ofrecerá una actualización corporativa y participará en reuniones individuales durante la

Theriva™ Biologics participará en la conferencia BIO-Europe Spring Read More »

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

November 13, 2023 08:00 ET – VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023

November 13, 2023 08:00 ET – VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma ductal de páncreas metastásico, sigue el curso previsto para completar la inscripción en el primer semestre de 2024; muchos pacientes han recibido la segunda dosis de VCN-01, que sigue siendo bien tolerado y mantiene

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023 Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2023

August 09, 2023 12:43 ET – Inicio de la dosificación en centros de EE. UU. de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Las segundas dosis de VCN-01 intravenoso administradas a pacientes en España fueron bien toleradas y presentaron un perfil de

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2023 Read More »

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

August 08, 2023 08:00 ET – Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma -Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated with a safety profile consistent with prior clinical trials – -VIRAGE remains on

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results Read More »

Our Pipeline

OVERVIEW Theriva™ Biologics’ oncolytic viruses have the potential to treat a broad range of difficult-to-treat tumor types and may be combined with a variety of cancer therapies. In the on-going VIRAGE Phase 2 clinical trial in patients with PDAC, VCN-01 is being tested in combination with standard-of-care chemotherapy gemcitabine/nab-paclitaxel. VCN-01 was also administered with the

Our Pipeline Read More »

Our Science

The Theriva™ Difference Theriva is developing highly differentiated oncolytic adenoviruses that are designed to overcome the challenges of accessibility, availability, and administration and can potentially enable multiple dosing to improve efficacy. The unique therapeutic properties of Theriva’s oncolytic viruses represent a new class of cancer treatments that are designed to selectively destroy tumor cells and

Our Science Read More »

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Initiated a Phase 1 Multiple Ascending Dose Clinical Trial of SYN-020 in Healthy Adult Volunteers; Topline Data Readout Expected in Q2 2022 Enrollment Remains Ongoing in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients Reports $72.1 Million of Cash on Hand to Fund Clinical Programs Through Key Milestones Beyond 2022 ROCKVILLE, Md., Nov.

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Read More »

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Phase 1 Single-Ascending Dose Clinical Trial of SYN-020 Demonstrated Favorable Safety Profile and was Well Tolerated at All Dose Levels; A Second Phase 1 Multiple-Ascending Dose Clinical Trial Expected to Commence in Q3 2021 Enrollment in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients Proceeding as Planned Reports $74.3 Million of Cash on

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Read More »